meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib
nivolumab based treatment
nivolumab alone
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs alkylating agents
vs dacarbazine
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs anti-PD-(L)1
vs pembrolizumab based treatment
vs pembrolizumab alone
All patients
Age < 65y (younger)
Age > 65y
Age > 75y (older)
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
metastasis (brain) NO
metastasis (brain) YES
metastasis (liver )
PD-L1 < 5%
PD-L1 > 5%
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC)
Prior anti-CTLA4 benefit NO
Prior anti-CTLA4 benefit YES
stage III (locally advanced)
stage IV (metastatic)
stage M0/M1A/M1B
stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
deaths (OS) (extension)
DOR
DOR (extension)
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
SAE (any grade)
SAE (grade 3-4)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
Abdominal pain TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Cough TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Hypersensitivity TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancytopenia TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Vitiligo TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Abdominal pain AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Constipation AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Dermatitis acneiform AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Increased Lipase Level AE (grade 3-4)
Nausea AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Rash maculopapular AE (grade 3-4)
Sepsis AE (grade 3-4)
Vomiting AE (grade 3-4)
DCR
mML - L1 - BRAF wild
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - BRAF wild
versus dacarbazine
nivolumab alone vs. dacarbazine
1
-
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone
1
certainty unassessable
-8%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open